Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Stock Holdings Boosted by BNP Paribas Financial Markets

BNP Paribas Financial Markets boosted its stake in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 80.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 285,111 shares of the company's stock after buying an additional 127,249 shares during the period. BNP Paribas Financial Markets owned approximately 0.50% of Ginkgo Bioworks worth $2,800,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of DNA. Erste Asset Management GmbH grew its stake in Ginkgo Bioworks by 47.9% during the 4th quarter. Erste Asset Management GmbH now owns 739,332 shares of the company's stock worth $6,979,000 after purchasing an additional 239,332 shares in the last quarter. Forbes J M & Co. LLP raised its position in Ginkgo Bioworks by 461.4% in the fourth quarter. Forbes J M & Co. LLP now owns 701,732 shares of the company's stock worth $6,891,000 after acquiring an additional 576,732 shares in the last quarter. Geode Capital Management LLC boosted its position in Ginkgo Bioworks by 4.9% during the fourth quarter. Geode Capital Management LLC now owns 437,025 shares of the company's stock worth $4,294,000 after purchasing an additional 20,394 shares in the last quarter. Monaco Asset Management SAM increased its stake in shares of Ginkgo Bioworks by 3.9% during the 4th quarter. Monaco Asset Management SAM now owns 384,664 shares of the company's stock worth $3,777,000 after purchasing an additional 14,539 shares in the last quarter. Finally, Prescott Group Capital Management L.L.C. raised its holdings in shares of Ginkgo Bioworks by 33.1% in the fourth quarter. Prescott Group Capital Management L.L.C. now owns 361,750 shares of the company's stock worth $3,552,000 after acquiring an additional 90,000 shares during the last quarter. Institutional investors and hedge funds own 78.63% of the company's stock.

Ginkgo Bioworks Price Performance

DNA stock traded up $0.14 during midday trading on Monday, hitting $8.07. The stock had a trading volume of 656,934 shares, compared to its average volume of 1,462,219. The company's 50-day moving average price is $7.17 and its 200 day moving average price is $9.08. Ginkgo Bioworks Holdings, Inc. has a 12-month low of $5.00 and a 12-month high of $33.20. The firm has a market cap of $468.33 million, a PE ratio of -0.62 and a beta of 1.29.

Ginkgo Bioworks (NYSE:DNA - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share for the quarter, missing analysts' consensus estimates of ($1.23) by ($0.35). Ginkgo Bioworks had a negative net margin of 298.78% and a negative return on equity of 58.54%. The firm had revenue of $48.32 million during the quarter, compared to analyst estimates of $38.70 million. As a group, sell-side analysts anticipate that Ginkgo Bioworks Holdings, Inc. will post -10.02 EPS for the current year.

Ginkgo Bioworks Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.